OncoMatch/Clinical Trials/NCT06883526

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

Is NCT06883526 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including ZG005 for and Gecacitinib Hydrochloride Tablets for lymphoma.

Phase 1/2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdNCT06883526Data as of May 2026

Treatment: ZG005 for · Gecacitinib Hydrochloride Tablets — PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify